Mechanisms of hepatic uptake, translocation and biliary excretion; drug transport; aberrant gastrointestinal drug absorption phenomena; pharmacokinetics

Dr. Brouwer is the George H. Cocolas Distinguished Professor and Chair of the Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, and Professor, Curriculum in Toxicology, at the University of North Carolina at Chapel Hill. She received her B.S. in Pharmacy (Oregon State University), completed a Pharm.D./Clinical Residency and Ph.D. in Pharmaceutical Sciences/Pharmacokinetics, and postdoctoral training (Pharmacology/Drug Metabolism) at the University of Kentucky before joining the faculty at the University of North Carolina in 1986. Dr. Brouwer directs an NIH-funded research program focused on hepatobiliary drug disposition and development/refinement of in vitro model systems to predict in vivo hepatobiliary disposition, drug interactions, and hepatotoxicity. Dr. Brouwer has mentored over 75 undergraduate, graduate and postdoctoral students, and published more than 260 research papers, abstracts, and book chapters. Dr. Brouwer is a co-inventor of B-CLEAR™ (United States Patent No. 6,780,580), an in vitro method to assess hepatic uptake, excretion and biliary clearance that correlates with in vivo data - this technology has been exclusively licensed from The University of North Carolina at Chapel Hill to Qualyst, Inc. Dr. Brouwer is a Qualyst founder and Chairs the Scientific Advisory Board. She served as a member of the NIH Pharmacology Study Section (1998-2002), and is a member of the editorial boards for Drug Metabolism and Disposition, Pharmaceutical Research, Journal of Pharmaceutical Sciences, and the AAPS Journal. She was elected an AAPS Fellow in 1998, and was recipient of the PHRMA Foundation Award in Excellence in Pharmaceutics in 2001.

News:
Dr. Brouwer's NIH Grant (R01 GM-41935) entitled "Altered Hepatic Disposition of Anionic Drugs: Mechanisms" was renewed for Years 14-17 effective July 1, 2005. Dr. Brouwer has been invited to speak at the 1st FEBS Special Meeting: "ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Disease", to be held in Innsbruck from March 4-10, 2006. In addition, she will participate in a symposium at the 9th European ISSX Meeting that is scheduled to take place in Manchester, UK from June 4-7, 2006, on the topic of Drug Transporters.